{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:47:15Z","timestamp":1787496435624,"version":"build-2736575974"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Interdiscip Sci Comput Life Sci"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12539-021-00437-4","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T07:03:36Z","timestamp":1624259016000},"page":"801-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review"],"prefix":"10.1007","volume":"13","author":[{"given":"Kang","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"issue":"280","key":"437_CR1","doi-asserted-by":"publisher","first-page":"280rv282","DOI":"10.1126\/scitranslmed.aaa6853","volume":"7","author":"C McDonald-Hyman","year":"2015","unstructured":"McDonald-Hyman C, Turka LA, Blazar BR (2015) Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med 7(280):280rv282. https:\/\/doi.org\/10.1126\/scitranslmed.aaa6853","journal-title":"Sci Transl Med"},{"issue":"4S Suppl2","key":"437_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/tp.0000000000001651","volume":"101","author":"JM Neuberger","year":"2017","unstructured":"Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Kr\u00e4mer BK, Metselaar HJ, Nevens F, Pirenne J, Rodr\u00edguez-Per\u00e1lvarez ML, Samuel D, Schneeberger S, Ser\u00f3n D, Trune\u010dka P, Tisone G, van Gelder T (2017) Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group. Transplantation 101(4S Suppl2):S1-s56. https:\/\/doi.org\/10.1097\/tp.0000000000001651","journal-title":"Transplantation"},{"key":"437_CR3","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15393.1","author":"KC Meyer","year":"2018","unstructured":"Meyer KC (2018) Recent advances in lung transplantation. F1000Research. https:\/\/doi.org\/10.12688\/f1000research.15393.1","journal-title":"F1000Research"},{"issue":"4","key":"437_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.transci.2017.07.005","volume":"56","author":"E Cozzi","year":"2017","unstructured":"Cozzi E, Colpo A, De Silvestro G (2017) The mechanisms of rejection in solid organ transplantation. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 56(4):498\u2013505. https:\/\/doi.org\/10.1016\/j.transci.2017.07.005","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"issue":"2","key":"437_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.path.2018.02.011","volume":"11","author":"J Koo","year":"2018","unstructured":"Koo J, Wang HL (2018) Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes. Surg Pathol Clin 11(2):431\u2013452. https:\/\/doi.org\/10.1016\/j.path.2018.02.011","journal-title":"Surg Pathol Clin"},{"issue":"9581","key":"437_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0140-6736(07)61050-2","volume":"370","author":"AE Grulich","year":"2007","unstructured":"Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (London, England) 370(9581):59\u201367. https:\/\/doi.org\/10.1016\/s0140-6736(07)61050-2","journal-title":"Lancet (London, England)"},{"issue":"1","key":"437_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20(1):25\u201339. https:\/\/doi.org\/10.1038\/s41577-019-0218-4","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"437_CR8","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 26(17):3009\u20133025. https:\/\/doi.org\/10.2174\/0929867324666170804143706","journal-title":"Curr Med Chem"},{"issue":"8","key":"437_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"10027","key":"437_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Jr Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7","journal-title":"Lancet (London, England)"},{"issue":"10031","key":"437_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/s0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 387(10031):1909\u20131920. https:\/\/doi.org\/10.1016\/s0140-6736(16)00561-4","journal-title":"Lancet (London, England)"},{"issue":"10","key":"437_CR12","doi-asserted-by":"publisher","first-page":"e11150","DOI":"10.7759\/cureus.11150","volume":"12","author":"O Al Jarroudi","year":"2020","unstructured":"Al Jarroudi O, Ulusakarya A, Almohamad W, Afqir S, Morere JF (2020) Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases. Cureus 12(10):e11150. https:\/\/doi.org\/10.7759\/cureus.11150","journal-title":"Cureus"},{"issue":"1","key":"437_CR13","doi-asserted-by":"publisher","first-page":"e636","DOI":"10.1097\/txd.0000000000001090","volume":"7","author":"D Amara","year":"2021","unstructured":"Amara D, Wisel SA, Braun HJ, Collisson EA, Friedlander T, Worner G, Roll GR, Hirose R, Stock PG (2021) Metastatic donor-derived malignancies following simultaneous pancreas-kidney transplant: three case reports and management strategies. Transplant Dir 7(1):e636. https:\/\/doi.org\/10.1097\/txd.0000000000001090","journal-title":"Transplant Dir"},{"issue":"2","key":"437_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jceh.2019.11.009","volume":"10","author":"W Amjad","year":"2020","unstructured":"Amjad W, Kotiah S, Gupta A, Morris M, Liu L, Thuluvath PJ (2020) Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with Nivolumab. J Clin Exp Hepatol 10(2):185\u2013187. https:\/\/doi.org\/10.1016\/j.jceh.2019.11.009","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"437_CR15","doi-asserted-by":"publisher","first-page":"e00416","DOI":"10.14309\/crj.0000000000000416","volume":"7","author":"C Anugwom","year":"2020","unstructured":"Anugwom C, Leventhal T (2020) Nivolumab-induced autoimmune-like cholestatic hepatitis in a liver transplant recipient. ACG Case Rep J 7(7):e00416. https:\/\/doi.org\/10.14309\/crj.0000000000000416","journal-title":"ACG Case Rep J"},{"issue":"2","key":"437_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","volume":"376","author":"R Barnett","year":"2017","unstructured":"Barnett R, Barta VS, Jhaveri KD (2017) Preserved renal-allograft function and the PD-1 pathway inhibitor Nivolumab. N Engl J Med 376(2):191\u2013192. https:\/\/doi.org\/10.1056\/NEJMc1614298","journal-title":"N Engl J Med"},{"issue":"1","key":"437_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdx548","volume":"29","author":"P Biondani","year":"2018","unstructured":"Biondani P, De Martin E, Samuel D (2018) Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol 29(1):286\u2013287. https:\/\/doi.org\/10.1093\/annonc\/mdx548","journal-title":"Ann Oncol"},{"issue":"8","key":"437_CR18","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/ajt.13786","volume":"16","author":"CL Boils","year":"2016","unstructured":"Boils CL, Aljadir DN, Cantafio AW (2016) Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg 16(8):2496\u20132497. https:\/\/doi.org\/10.1111\/ajt.13786","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"issue":"9","key":"437_CR19","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.jtho.2020.01.026","volume":"15","author":"M Braun","year":"2020","unstructured":"Braun M, Fuchs V, Kian W, Roisman L, Peled N, Rosenberg E, Friedel L (2020) Nivolumab induced hepatocanalicular cholestasis and liver rejection in a patient with lung cancer and liver transplant. J Thorac Oncol 15(9):e149\u2013e150. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.026","journal-title":"J Thorac Oncol"},{"issue":"9","key":"437_CR20","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/j.transproceed.2020.06.012","volume":"52","author":"AG Cuenca","year":"2020","unstructured":"Cuenca AG, Rosales I, Lee RJ, Wu CL, Colvin R, Feldman AS, Efstathiou JA, Tolkoff-Rubin N, Elias N (2020) Resolution of a high grade and metastatic bk polyomavirus-associated urothelial cell carcinoma following radical allograft nephroureterectomy and immune checkpoint treatment: a case report. Transpl Proc 52(9):2720\u20132725. https:\/\/doi.org\/10.1016\/j.transproceed.2020.06.012","journal-title":"Transpl Proc"},{"issue":"9","key":"437_CR21","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","volume":"69","author":"MJ Danesh","year":"2020","unstructured":"Danesh MJ, Mulvaney PM, Murakami N, Riella LV, Silk AW, Hanna GJ, Schmults CD (2020) Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy. Cancer Immunol Immunother CII 69(9):1937\u20131941. https:\/\/doi.org\/10.1007\/s00262-020-02644-2","journal-title":"Cancer Immunol Immunother CII"},{"issue":"6","key":"437_CR22","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","volume":"152","author":"EN De Toni","year":"2017","unstructured":"De Toni EN, Gerbes AL (2017) Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient. Gastroenterology 152(6):1631\u20131633. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.063","journal-title":"Gastroenterology"},{"issue":"6","key":"437_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","volume":"9","author":"TT DeLeon","year":"2018","unstructured":"DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ (2018) Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol 9(6):1054\u20131062. https:\/\/doi.org\/10.21037\/jgo.2018.07.05","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"437_CR24","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/annonc\/mdx281","volume":"28","author":"S Dueland","year":"2017","unstructured":"Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017) Acute liver graft rejection after ipilimumab therapy. Ann Oncol 28(10):2619\u20132620. https:\/\/doi.org\/10.1093\/annonc\/mdx281","journal-title":"Ann Oncol"},{"key":"437_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26682","author":"BD Friend","year":"2017","unstructured":"Friend BD, Venick RS, McDiarmid SV, Zhou X, Naini B, Wang H, Farmer DG, Busuttil RW, Federman N (2017) Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26682","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"437_CR26","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1097\/txd.0000000000000814","volume":"4","author":"D Gassmann","year":"2018","unstructured":"Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, N\u00e4geli M, Mangana J, M\u00fcllhaupt B, Jenni F, Misselwitz B (2018) Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Dir 4(8):e376. https:\/\/doi.org\/10.1097\/txd.0000000000000814","journal-title":"Transplant Dir"},{"issue":"1","key":"437_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12882-018-1003-5","volume":"19","author":"JW Goldman","year":"2018","unstructured":"Goldman JW, Abdalla B, Mendenhall MA, Sisk A, Hunt J, Danovitch GM, Lum EL (2018) PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin\u2014case report. BMC Nephrol 19(1):210. https:\/\/doi.org\/10.1186\/s12882-018-1003-5","journal-title":"BMC Nephrol"},{"issue":"4","key":"437_CR28","doi-asserted-by":"publisher","first-page":"Mmt10","DOI":"10.2217\/mmt-2018-0004","volume":"5","author":"MJ Grant","year":"2018","unstructured":"Grant MJ, DeVito N, Salama AKS (2018) Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. Melanoma Manag 5(4):Mmt10. https:\/\/doi.org\/10.2217\/mmt-2018-0004","journal-title":"Melanoma Manag"},{"key":"437_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2018.12.027","volume":"109","author":"J Gueguen","year":"2019","unstructured":"Gueguen J, Bailly E, Machet L, Miquelestorena-Standley E, Stefic K, Gatault P, B\u00fcchler M (2019) CMV disease and colitis in a kidney transplanted patient under pembrolizumab. Eur J Cancer (Oxford, England: 1990) 109:172\u2013174. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.027","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"3","key":"437_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/cmr.0000000000000651","volume":"30","author":"DL Hanna","year":"2020","unstructured":"Hanna DL, Law SJ, Merrick SA, Heptinstall L, Bass P, Dupont P, Sheri A (2020) The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma. Melanoma Res 30(3):321\u2013324. https:\/\/doi.org\/10.1097\/cmr.0000000000000651","journal-title":"Melanoma Res"},{"key":"437_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","volume":"67","author":"S Herz","year":"2016","unstructured":"Herz S, H\u00f6fer T, Papapanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, Ugurel S, Roesch A, Livingstone E, Schilling B, Franklin C (2016) Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer (Oxford, England: 1990) 67:66\u201372. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.026","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"1","key":"437_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","volume":"7","author":"DP Hurkmans","year":"2019","unstructured":"Hurkmans DP, Verhoeven J, de Leur K, Boer K, Joosse A, Baan CC, von der Th\u00fcsen JH, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM, Hesselink DA (2019) Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. J Immunother Cancer 7(1):182. https:\/\/doi.org\/10.1186\/s40425-019-0653-6","journal-title":"J Immunother Cancer"},{"issue":"9","key":"437_CR33","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.transproceed.2016.07.019","volume":"48","author":"A Jose","year":"2016","unstructured":"Jose A, Yiannoullou P, Bhutani S, Denley H, Morton M, Picton M, Summers A, van Dellen D, Augustine T (2016) Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature. Transpl Proc 48(9):3137\u20133141. https:\/\/doi.org\/10.1016\/j.transproceed.2016.07.019","journal-title":"Transpl Proc"},{"issue":"6","key":"437_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","volume":"25","author":"V Kumar","year":"2020","unstructured":"Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, Rahma OE (2020) The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 25(6):505\u2013514. https:\/\/doi.org\/10.1634\/theoncologist.2019-0659","journal-title":"Oncologist"},{"issue":"1","key":"437_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/cmr.0000000000000410","volume":"28","author":"JC Kuo","year":"2018","unstructured":"Kuo JC, Lilly LB, Hogg D (2018) Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Res 28(1):61\u201364. https:\/\/doi.org\/10.1097\/cmr.0000000000000410","journal-title":"Melanoma Res"},{"key":"437_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","volume":"102","author":"S Le Fournis","year":"2016","unstructured":"Le Fournis S, Gohier P, Urban T, Jeanfaivre T, Hureaux J (2016) Corneal graft rejection in a patient treated with nivolumab for primary lung cancer. Lung Cancer 102:28\u201329. https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.008","journal-title":"Lung Cancer"},{"issue":"9","key":"437_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG (2016) Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 374(9):896\u2013898. https:\/\/doi.org\/10.1056\/NEJMc1509268","journal-title":"N Engl J Med"},{"issue":"19","key":"437_CR38","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/jco.2013.49.2314","volume":"32","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Bodell MA, Kraus ES, Sharfman WH (2014) Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 32(19):e69-71. https:\/\/doi.org\/10.1200\/jco.2013.49.2314","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"437_CR39","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/ajt.15856","volume":"20","author":"EJ Lipson","year":"2020","unstructured":"Lipson EJ, Naqvi FF, Loss MJ, Schollenberger MD, Pardoll DM, Moore J Jr, Brennan DC (2020) Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 20(8):2264\u20132268. https:\/\/doi.org\/10.1111\/ajt.15856","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"11","key":"437_CR40","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3201\/eid2511.190705","volume":"25","author":"C Medrano","year":"2019","unstructured":"Medrano C, Vergez F, Mengelle C, Faguer S, Kamar N, Del Bello A (2019) Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy. Emerg Infect Dis 25(11):2145\u20132147. https:\/\/doi.org\/10.3201\/eid2511.190705","journal-title":"Emerg Infect Dis"},{"key":"437_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16326","author":"CD Mejia","year":"2020","unstructured":"Mejia CD, Frank AM, Singh P, Yadav A (2020) Immune checkpoint inhibitor therapy-associated graft intolerance syndrome in a failed kidney transplant recipient. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. https:\/\/doi.org\/10.1111\/ajt.16326","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"5","key":"437_CR42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","volume":"3","author":"DM Miller","year":"2017","unstructured":"Miller DM, Faulkner-Jones BE, Stone JR, Drews RE (2017) Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Rep 3(5):412\u2013415. https:\/\/doi.org\/10.1016\/j.jdcr.2017.06.005","journal-title":"JAAD Case Rep"},{"key":"437_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","volume":"3","author":"RE Morales","year":"2015","unstructured":"Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD (2015) Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 3:22. https:\/\/doi.org\/10.1186\/s40425-015-0066-0","journal-title":"J Immunother Cancer"},{"key":"437_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","volume":"4","author":"M Ong","year":"2016","unstructured":"Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G (2016) Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer 4:64. https:\/\/doi.org\/10.1186\/s40425-016-0171-8","journal-title":"J Immunother Cancer"},{"issue":"1","key":"437_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","volume":"66","author":"TK Owonikoko","year":"2017","unstructured":"Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, Nautiyal V, Chatwal MS, Book WM, Sahu A, Sica GL, Ahmed R, Ramalingam SS (2017) Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother CII 66(1):45\u201350. https:\/\/doi.org\/10.1007\/s00262-016-1918-2","journal-title":"Cancer Immunol Immunother CII"},{"key":"437_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220934160","author":"SA Padala","year":"2020","unstructured":"Padala SA, Patel SK, Vakiti A, Patel N, Gani I, Kapoor R, Muhammad S (2020) Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/1078155220934160","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"5","key":"437_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/imt-2020-0014","volume":"12","author":"A Pandey","year":"2020","unstructured":"Pandey A, Cohen DJ (2020) Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection. Immunotherapy 12(5):287\u2013292. https:\/\/doi.org\/10.2217\/imt-2020-0014","journal-title":"Immunotherapy"},{"issue":"9","key":"437_CR48","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.rmr.2019.08.004","volume":"36","author":"H Pluchart","year":"2019","unstructured":"Pluchart H, Ferrer L, Giovannini D, Tetaz R, Pinsolle J, Stephanov O, Giaj Levra M, Moro-Sibilot D, Toffart AC (2019) Concomitant use of nivolumab and immunosuppressants in a renal transplant patient. Rev Mal Respir 36(9):1064\u20131068. https:\/\/doi.org\/10.1016\/j.rmr.2019.08.004","journal-title":"Rev Mal Respir"},{"issue":"4","key":"437_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/mmt.15.27","volume":"2","author":"R Qin","year":"2015","unstructured":"Qin R, Salama AK (2015) Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. Melanoma Manag 2(4):311\u2013314. https:\/\/doi.org\/10.2217\/mmt.15.27","journal-title":"Melanoma Manag"},{"issue":"3","key":"437_CR50","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/hep.29575","volume":"67","author":"A Rammohan","year":"2018","unstructured":"Rammohan A, Reddy MS, Farouk M, Vargese J, Rela M (2018) Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? Hepatology (Baltimore, MD) 67(3):1166\u20131168. https:\/\/doi.org\/10.1002\/hep.29575","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"437_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/cji.0000000000000077","volume":"38","author":"HA Ranganath","year":"2015","unstructured":"Ranganath HA, Panella TJ (2015) Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother (Hagerstown, Md: 1997) 38(5):211. https:\/\/doi.org\/10.1097\/cji.0000000000000077","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"3","key":"437_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/jop.2017.027326","volume":"14","author":"M Sadaat","year":"2018","unstructured":"Sadaat M, Jang S (2018) Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy. J Oncol Pract 14(3):198\u2013199. https:\/\/doi.org\/10.1200\/jop.2017.027326","journal-title":"J Oncol Pract"},{"issue":"5","key":"437_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7326\/l17-0187","volume":"167","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman G, Perez K, Sood G, Katkhuda R, Tawbi H (2017) Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma. Ann Intern Med 167(5):361\u2013362. https:\/\/doi.org\/10.7326\/l17-0187","journal-title":"Ann Intern Med"},{"issue":"2","key":"437_CR54","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/tp.0000000000002502","volume":"103","author":"P Singh","year":"2019","unstructured":"Singh P, Von Visger J, Prosek J, Rovin B, Pesavento TE, Olencki T, Pandey D (2019) Preserved renal allograft function and successful treatment of metastatic merkel cell cancer post nivolumab therapy. Transplantation 103(2):e52\u2013e53. https:\/\/doi.org\/10.1097\/tp.0000000000002502","journal-title":"Transplantation"},{"issue":"2","key":"437_CR55","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.transproceed.2019.09.014","volume":"52","author":"I Soellradl","year":"2020","unstructured":"Soellradl I, Kehrer H, Cejka D (2020) Use of Ipilimumab and Pembrolizumab in metastatic melanoma in a combined heart and kidney transplant recipient: a case report. Transpl Proc 52(2):657\u2013659. https:\/\/doi.org\/10.1016\/j.transproceed.2019.09.014","journal-title":"Transpl Proc"},{"issue":"6","key":"437_CR56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","volume":"27","author":"L Spain","year":"2016","unstructured":"Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J (2016) Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 27(6):1135\u20131137. https:\/\/doi.org\/10.1093\/annonc\/mdw130","journal-title":"Ann Oncol"},{"key":"437_CR57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","volume":"104","author":"M Tio","year":"2018","unstructured":"Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM (2018) Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV\u00a0or hepatitis B\/C infection. Eur J Cancer (Oxford, England: 1990) 104:137\u2013144. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.017","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"437_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000908","author":"MH Trager","year":"2020","unstructured":"Trager MH, Coley SM, Dube G, Khan S, Ingham M, Samie FH, Geskin LJ, McDonnell D, Brouder D, Saenger Y, Carvajal R (2020) Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. J Immunother cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000908","journal-title":"J Immunother cancer"},{"key":"437_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13539","author":"I Tsung","year":"2020","unstructured":"Tsung I, Worden FP, Fontana RJ (2020) A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist. https:\/\/doi.org\/10.1002\/onco.13539","journal-title":"Oncologist"},{"issue":"11","key":"437_CR60","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/ico.0000000000002372","volume":"39","author":"E Vahonsebrouck","year":"2020","unstructured":"Vahonsebrouck E, Van De Walle Mn E, Lybaert W, Kruse V, Roels D (2020) Bilateral corneal graft rejection associated with pembrolizumab treatment. Cornea 39(11):1436\u20131438. https:\/\/doi.org\/10.1097\/ico.0000000000002372","journal-title":"Cornea"},{"issue":"5","key":"437_CR61","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/tp.0000000000002914","volume":"104","author":"K Venkatachalam","year":"2020","unstructured":"Venkatachalam K, Malone AF, Heady B, Santos RD, Alhamad T (2020) Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients. Transplantation 104(5):1041\u20131047. https:\/\/doi.org\/10.1097\/tp.0000000000002914","journal-title":"Transplantation"},{"issue":"9","key":"437_CR62","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/cji.0000000000000188","volume":"40","author":"JK Winkler","year":"2017","unstructured":"Winkler JK, Gutzmer R, Bender C, Lang N, Zeier M, Enk AH, Hassel JC (2017) Safe administration of An anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature. J Immunother (Hagerstown, Md: 1997) 40(9):341\u2013344. https:\/\/doi.org\/10.1097\/cji.0000000000000188","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"9","key":"437_CR63","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1016\/j.transproceed.2019.08.002","volume":"51","author":"K Wong","year":"2019","unstructured":"Wong K, Shen J, D\u2019Ambruoso S, Stefanoudakis D, Drakaki A (2019) Safety and efficacy of immune checkpoint inhibitors in patients with metastatic cancer post solid organ transplantation: a case report and review of the literature. Transpl Proc 51(9):3053\u20133058. https:\/\/doi.org\/10.1016\/j.transproceed.2019.08.002","journal-title":"Transpl Proc"},{"issue":"11","key":"437_CR64","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1093\/annonc\/mdx409","volume":"28","author":"CK Wu","year":"2017","unstructured":"Wu CK, Juang GD, Lai HC (2017) Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration. Ann Oncol 28(11):2895\u20132896. https:\/\/doi.org\/10.1093\/annonc\/mdx409","journal-title":"Ann Oncol"},{"issue":"12","key":"437_CR65","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1111\/ajt.15071","volume":"18","author":"O Zehou","year":"2018","unstructured":"Zehou O, Leibler C, Arnault JP, Sayegh J, Montaudi\u00e9 H, R\u00e9my P, Glotz D, Cordonnier C, Martin L, Lebb\u00e9 C (2018) Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 18(12):3065\u20133071. https:\/\/doi.org\/10.1111\/ajt.15071","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"1","key":"437_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.hbpd.2019.09.011","volume":"19","author":"L Zhuang","year":"2020","unstructured":"Zhuang L, Mou HB, Yu LF, Zhu HK, Yang Z, Liao Q, Zheng SS (2020) Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int: HBPD INT 19(1):91\u201393. https:\/\/doi.org\/10.1016\/j.hbpd.2019.09.011","journal-title":"Hepatobiliary Pancreat Dis Int: HBPD INT"},{"issue":"3","key":"437_CR67","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/ajt.15617","volume":"20","author":"MF Nordness","year":"2020","unstructured":"Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, O\u2019Dell H, Perri RE, Alexopoulos SP (2020) Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant 20(3):879\u2013883. https:\/\/doi.org\/10.1111\/ajt.15617","journal-title":"Am J Transplant"},{"issue":"10","key":"437_CR68","doi-asserted-by":"publisher","first-page":"S981","DOI":"10.1016\/j.jtho.2019.08.2155","volume":"14","author":"C Dutra","year":"2019","unstructured":"Dutra C, Garcia BR, Vieira R, Figueiredo AC, N\u00e9ron Y (2019) EP1.04\u201332 successful corneal transplantation in a patient treated with nivolumab for metastatic non-small cell lung cancer. J Thorac Oncol 14(10):S981. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.2155","journal-title":"J Thorac Oncol"},{"key":"437_CR69","doi-asserted-by":"publisher","first-page":"S1251","DOI":"10.14309\/01.ajg.0000598472.41771.5f","volume":"114","author":"S Kumar","year":"2019","unstructured":"Kumar S (2019) Nivolumab-induced severe allograft rejection in recurrent post-transplant hepatocellular carcinoma. Am J Gastroenterol 114:S1251\u2013S1252. https:\/\/doi.org\/10.14309\/01.ajg.0000598472.41771.5f","journal-title":"Am J Gastroenterol"},{"key":"437_CR70","first-page":"119","volume":"12","author":"V Kwatra","year":"2016","unstructured":"Kwatra V, Karanth N, Priyadarshana K, Charakidis M (2016) Pembrolizumab for metastatic melanoma in renal allograft recipient with subsequent graft rejection and treatment response failure, a case report. Asia Pac J Clin Oncol 12:119\u2013120","journal-title":"Asia Pac J Clin Oncol"},{"key":"437_CR71","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/ajt.15406","volume":"19","author":"BT Lee","year":"2019","unstructured":"Lee BT, Han H, Chopra S, Aheam AJ (2019) Nivolumab-induced rejection of a liver allograft: PD-1 inhibition thwarts liver allograft resistance to humoral rejection. Am J Transplant 19:1077\u20131078. https:\/\/doi.org\/10.1111\/ajt.15406","journal-title":"Am J Transplant"},{"key":"437_CR72","first-page":"337","volume":"32","author":"J Verhoeven","year":"2019","unstructured":"Verhoeven J, Hurkmans D, de Leur K, Boer K, Joosse A, Baan C, von der Th\u00fcsen J, Van Schaik R, Mathijssen R, Van Der Veldt A, Hesselink D (2019) Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. Transpl Int 32:337","journal-title":"Transpl Int"},{"issue":"2","key":"437_CR73","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00520-019-04869-z","volume":"28","author":"BR Chae","year":"2020","unstructured":"Chae BR, Kim YJ, Lee YS (2020) Prognostic accuracy of the sequential organ failure assessment (SOFA) and quick SOFA for mortality in cancer patients with sepsis defined by systemic inflammatory response syndrome (SIRS). Support Care Cancer Off J Multinatl Assoc Support Care Cancer 28(2):653\u2013659. https:\/\/doi.org\/10.1007\/s00520-019-04869-z","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"7","key":"437_CR74","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/s1470-2045(11)70144-9","volume":"12","author":"A Vitale","year":"2011","unstructured":"Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegn\u00f9 L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U (2011) Barcelona clinic liver cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 12(7):654\u2013662. https:\/\/doi.org\/10.1016\/s1470-2045(11)70144-9","journal-title":"Lancet Oncol"},{"issue":"10","key":"437_CR75","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/s1470-2045(19)30418-8","volume":"20","author":"AC Dietz","year":"2019","unstructured":"Dietz AC, Seidel K, Leisenring WM, Mulrooney DA, Tersak JM, Glick RD, Burnweit CA, Green DM, Diller LR, Smith SA, Howell RM, Stovall M, Armstrong GT, Oeffinger KC, Robison LL, Termuhlen AM (2019) Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol 20(10):1420\u20131431. https:\/\/doi.org\/10.1016\/s1470-2045(19)30418-8","journal-title":"Lancet Oncol"},{"issue":"3","key":"437_CR76","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/tp.0000000000001192","volume":"101","author":"SA Acuna","year":"2017","unstructured":"Acuna SA, Huang JW, Daly C, Shah PS, Kim SJ, Baxter NN (2017) Outcomes of solid organ transplant recipients with preexisting malignancies in remission: a systematic review and meta-analysis. Transplantation 101(3):471\u2013481. https:\/\/doi.org\/10.1097\/tp.0000000000001192","journal-title":"Transplantation"},{"issue":"4","key":"437_CR77","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.trre.2017.08.003","volume":"31","author":"SA Acuna","year":"2017","unstructured":"Acuna SA, Huang JW, Dossa F, Shah PS, Kim SJ, Baxter NN (2017) Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando) 31(4):240\u2013248. https:\/\/doi.org\/10.1016\/j.trre.2017.08.003","journal-title":"Transplant Rev (Orlando)"},{"key":"437_CR78","unstructured":"Gogna S, Ramakrishna K, John S (2020) Post transplantation cancer. In: StatPearls. StatPearls Publishing, Copyright\u00a9 2020, StatPearls Publishing LLC., Treasure Island"},{"issue":"1","key":"437_CR79","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","volume":"10","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH (2019) Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat Commun 10(1):4712. https:\/\/doi.org\/10.1038\/s41467-019-12628-1","journal-title":"Nat Commun"},{"issue":"7","key":"437_CR80","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00228-017-2234-2","volume":"73","author":"S Lichtenberg","year":"2017","unstructured":"Lichtenberg S, Rahamimov R, Green H, Fox BD, Mor E, Gafter U, Chagnac A, Rozen-Zvi B (2017) The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation. Eur J Clin Pharmacol 73(7):819\u2013826. https:\/\/doi.org\/10.1007\/s00228-017-2234-2","journal-title":"Eur J Clin Pharmacol"},{"key":"437_CR81","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.intimp.2019.01.035","volume":"69","author":"N Saber-Moghaddam","year":"2019","unstructured":"Saber-Moghaddam N, Nomani H, Sahebkar A, Johnston TP, Mohammadpour AH (2019) The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation. Int Immunopharmacol 69:150\u2013158. https:\/\/doi.org\/10.1016\/j.intimp.2019.01.035","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"437_CR82","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.1111\/ctr.12134","volume":"27","author":"J He","year":"2013","unstructured":"He J, Li Y, Zhang H, Wei X, Zheng H, Xu C, Bao X, Yuan X, Hou J (2013) Immune function assay (ImmuKnow) as a predictor of allograft rejection and infection in kidney transplantation. Clin Transplant 27(4):E351-358. https:\/\/doi.org\/10.1111\/ctr.12134","journal-title":"Clin Transplant"},{"issue":"9","key":"437_CR83","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.15811","volume":"20","author":"T d'Izarny-Gargas","year":"2020","unstructured":"d\u2019Izarny-Gargas T, Durrbach A, Zaidan M (2020) Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 20(9):2457\u20132465. https:\/\/doi.org\/10.1111\/ajt.15811","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"437_CR84","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"issue":"7","key":"437_CR85","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","volume":"6","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Ghidini M, Ghidini A, Tomasello G (2020) Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA Oncol 6(7):1068\u20131071. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1046","journal-title":"JAMA Oncol"}],"container-title":["Interdisciplinary Sciences: Computational Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12539-021-00437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12539-021-00437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12539-021-00437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T15:14:48Z","timestamp":1634310888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12539-021-00437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s12539-021-00437-4","relation":{},"ISSN":["1913-2751","1867-1462"],"issn-type":[{"value":"1913-2751","type":"print"},{"value":"1867-1462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study complied with ethics approval and consent and was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The study has received all consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The study has received all consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}